| Title | [Effects of sirolimus on the growth of transplanted hepatocellular carcinoma.] | | Author(s) | Zhang J, Li H, Wang GS, Jiang N, Yang Y, Chen GH | | Institution | Liver Transplantation Center, the Third Affiliated Hospital, Sun Yat-sen University, Guangzhou 510630, China. | | Source | Zhonghua Gan Zang Bing Za Zhi 2009 Jun; 17(6):413-6. | | Abstract | OBJECTIVE: To study the effects of sirolimus (SRL) on the growth of transplanted human hepatocellular carcinoma (HCC) in nude mice.
METHODS: HepG2 cells were Implanted into the liver of nude mice. The implanted mice were then treated with SRL and tacrolimus (FK506). The expression of vascular endothelial growth factor (VEGF) and proliferating cell nuclear antigen (PCNA) was detected by immunohistology, microvessel density (MVD) was counted by immunostaining with anti-CD34 antibody for endothelial cells. Tumor apoptosis was detected by terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay.
RESULTS: The tumor weight was (352+/-38) mg, (683+/-53) mg and (675+/-45) mg in SRL, FK506 and control group respectively. The tumor weight was significantly decreased in SRL group (P less than 0.01), and there was no difference between FK506 group and control group. The expression of VEGF and PCNA protein was remarkably down-regulated in SRL group compared to control group (P less than 0.05), and it was not significantly different between FK506 group and control group (P more than 0.05). Compared to the control group, MVD was significanly decreased in SRL group, and the apoptosis index of tumor cell was significantly higher in SRL group (P less than 0.01).
CONCLUSION: SRL inhibits transplanted HCC tumor growth by reducing tumor angiogenesis, inhibiting tumor proliferation and inducing tumor apoptosis. | | Language | chi | | Pub Type(s) | English Abstract
Journal Article
| | PubMed ID | 19567017 |
|
